ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

PhRMA Tightens DTC Restrictions, But Dingell Says It’s Not Enough.

December 12, 2008

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012

NCI Cooperative Group, Cancer Center Trials Listed

October 31, 2008

FDA says new tools needed to speed therapeutics development.

March 26, 2004

Obituary: Paul Rogers, Former Congressman, Instrumental In National Cancer Act Passage.

October 17, 2008

NCI-Approved Clinical Trials

April 29, 2005